we still have remaining share repurchase authorization of $num-one billion.
adjusted earnings per share was $num-one, and gaap earnings per share was $num-two.
in the fourth quarter, our global tavr sales were $num-one million, an increase of num-two% on an underlying basis, with impressive strength outside the u.s. in summary, despite a slower-than-expected start to the year, we continue to anticipate year-seven underlying tavr sales growth of num-three to num-four%, consistent with the range we shared at our december investor conference.
our fourth quarter sales were negatively impacted by the wave of covid that began late in the quarter, especially in the u.s. earnings per share in the quarter was below our expectations as it was impacted by weaker-than-expected sales and we accelerated certain spending into the fourth quarter of year-six that we had planned to incur during year-seven, including preparation for tmtt product launches.
year-six growth was driven by balanced contributions from all product lines led by hemosphere sales as capital spending resumed.
for the first quarter of year-seven, we project total sales to be between num-one and $num-two billion and adjusted earnings per share of $num-three to $num-four.
num-one largest health burden, we believe the opportunity to serve our patients will nearly double between now and num-two.